Doxorubicin has in vivo toxicological effects on ex vivo cultured mesenchymal stem cells

Toxicology Letters

Volumn 224, Issue 3, 2014, Pages 380-386

  Oliveira, Maira Souza ^a   Carvalho, Juliana Lott ^a   Campos, Ana Carolina De Angelis ^a   Gomes, Dawidson Assis ^a   de Goes, Alfredo Miranda ^a   Melo, Marília Martins ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Cardiac differentiation; Cell therapy; Drug toxicity; Mesenchymal stem cells

Indexed keywords

ALKALINE PHOSPHATASE; CELL SURFACE MARKER; CONNEXIN 43; DOXORUBICIN; SODIUM CHLORIDE; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOTRANSPLANTATION; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME SYNTHESIS; EX VIVO STUDY; HEART EJECTION FRACTION; HEART FAILURE; HEMATOPOIETIC STEM CELL; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 84890180035     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.11.023     Document Type: Article

References (40)

1. Aapro M., Bernard-Marty C., Brain E., Batist G., Erdkamp F., Krzemienjecki K.R., Lluch L., Monfardini A., Ryberg S., Soubeyran M., Wedding P.U. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann. Oncol. 2011, 22:257-267.
2. Assis A.C.M., Carvalho J.L., Jacoby B.A., Ferreira R.L.B., Castanheira P., Diniz S.O.F., Cardoso V.N., Goes A.M., Ferreira A.J. Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant. 2010, 19:219-230.
3. Barreto Filho J.B., Oliveira M.S. Placental structure and biological aspects of fetal membranes cultured in vitro. Biomedical Tissue Culture 2012, 115-132. In Tech, Rijeka, Croatia. L. Ceccherini-Nelli, B. Matteoli (Eds.).
4. Butany J., Ahn E., Luk A. Drug-related cardiac pathology. J. Clin. Pathol. 2009, 62:1074-1084.
5. Carvalho J.L., Braga V.B.A., Melo M.B., Campos A.C.D.A., Oliveira M.S., Gomes D.A., Ferreira A.J., Santos R.A.S., Goes A.M. Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction. J. Cell. Mol. Med. 2013, 17:617-625.
6. Chen Y., Liu W., Li W., Gao C. Autologous bone marrow mesenchymal cell transplantation improves left ventricular function in a rabbit model of dilated cardiomyopathy. Exp. Mol. Pathol. 2010, 88:311-315.
7. Dai W., Hale S.L., Martin B.J., Kuang J.-Q., Dow J.S., Wold L.E., Kloner R.A. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation 2005, 112:214-223.
8. De Angelis A., Piegari E., Cappetta D., Marino L., Filippelli A., Berrino L., Ferreira-Martins J., Zheng H., Hosoda T., Rota M., Urbanek K., Kajstura J., Leri A., Rossi F., Anversa P. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010, 121:276-292.
9. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
10. Du Y., Lou H. Catechin and proanthocyanidin B4 from grape seeds prevent doxorubicin-induced toxicity in cardiomyocytes. Eur. J. Pharmacol. 2008, 591:96-101.
11. Garbade J., Dhein S., Lipinski C., Aupperle H., Arsalan M., Borger M., Barten M.J., Lehmann S., Walther T., Mohr F.-W. Bone marrow-derived stem cells attenuate impaired contractility and enhance capillary density in a rabbit model of doxorubicin-induced failing hearts. J. Card. Surg. 2009, 24:591-599.
12. Gianni L., Herman E.H., Lipshultz S.E., Minotti G., Sarvazyan N., Sawyer D.B. Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 2008, 26:3777-3784.
13. Hazari M.S., Haykal-Coates N., Winsett D.W., Costa D.L., Farraj A.K. Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin. Toxicol. Sci. 2009, 110:224-234.
14. Henninger C., Huelsenbeck J., Huelsenbeck S., Grosch S., Schad A., Lackner K.J., Kaina B., Fritz G. The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 2012, 261:66-73.
15. Hou X.-W., Jiang Y., Wang L.-F., Xu H.-Y., Lin H.-M., He X.-Y., He J.-J., Zhang S. Protective role of granulocyte colony-stimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. Toxicol. Lett. 2009, 187:40-44.
16. Jiang W., Ma A., Wang T., Han K., Liu Y., Zhang Y., Dong A., Du Y., Huang X., Wang J., Lei X., Zheng X. Homing and differentiation of mesenchymal stem cells delivered intravenously to ischemic myocardium in vivo: a time-series study. Eur. J. Physiol. 2006, 453:43-52.
17. Kumar S.N., Konorev E.A., Aggarwal D., Kalyanaraman B. Analysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte. J. Proteomics 2011, 74:683-697.
18. Lahoti T.S., Patel D., Thekkemadom V., Beckett R., Ray S.D. Doxorubicin-induced in vivo nephrotoxicity involves oxidative stress-mediated multiple pro and anti-apoptotic signaling pathways. Curr. Neurovasc. Res. 2012, 9:282-295.
19. Lilyanna S., Martinez E.C., Vu T.D., Ling L.H., Gan S.U., Tan A.L., Phan T.T., Kofidis T. Cord lining-mesenchymal stem cells graft supplemented with an omental flap myocardial revascularization and ameliorates cardiac dysfunction in a rat model of chronic ischemic heart failure. Tissue Eng. A 2013, 19:1303-1315.
20. Lipshultz S.E., Miller T.L., Scully R.E., Lipsitz S.R., Rifai N., Silverman L.B., Colan S.D., Neuberg D.S., Dahlberg S.E., Henkel J.M., Asselin B.L., Athale U.H., Clavell L.A., Laverdière C., Michon B., Schorin M.A., Sallan S.E. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J. Clin. Oncol. 2012, 30:1042-1049.
21. Lipshultz S.E., Scully R.E., Lipsitz S.R., Sallan S.E., Silverman L.B., Miller T.L., Barry E.V., Asselin B.L., Athale U., Clavell L.A., Larsen E., Moghrabi A., Samson Y., Michon B., Schorin M.A., Cohen H.J., Neuberg D.S., Orav E.J., Colan S.D. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010, 11:950-961.
22. Machado V., Cabral A., Monteiro P., Gonçalves L., Providencia L.A. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). Rev. Port. Cardiol. 2008, 27:1277-1296.
23. Mayhall E.A., Paffett-Lugassy N., Zon L.I. The clinical potential of stem cells. Curr. Opin. Cell Biol. 2004, 16:713-720.
24. Mias C., Lairez O., Trouche E., Roncalli J., Calise D., Sequelas M.H., Ordener C. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 2009, 27:2734-2743.
25. Oliveira M.S., Melo M.B., Carvalho J.L., Melo I.M., Lavor M.S.L., Gomes D.A., Góes A.M., Melo M.M. Doxorubicin cardiotoxicity and cardiac function improvement after stem cell therapy diagnosed by strain echocardiography. J. Cancer Sci. Ther. 2013, 5:52-57.
26. Ott H.C., Matthiesen T.S., Goh S.K., Black L.D., Kren S.M., Netoff T.I., Taylor D.A. Perfusion-decellularized matrix: using nature' platform to engineer a bioartificial heart. Nat. Med. 2008, 14:213-221.
27. Paula A.C.C., Zonari A.A.C., Martins T.M., da M., Novikoff S., Silva A.R.P., Correlo V.M., Reis R.L., Gomes D.A., Goes A.M. Human serum is a suitable supplement for the osteogenic differentiation of human. Tissue Eng. A 2013, 19:277-289.
28. Planat-Bénard V., Menard C., André M., Puceat M., Perez A., Garcia-Verdugo J.-M., Pénicaud L., Casteilla L. Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ. Res. 2004, 94:223-229.
29. Rafiyath S.M., Rasul M., Lee B., Wei G., Lamba G., Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp. Hematol. Oncol. 2012, 1:1-9.
30. Saracchini S., Foltran L., Tuccia F., Bassini A., Sulfaro S., Micheli E., Del Conte A., Bertola M., Gion M., Lorenzon M., Tumolo S. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification. Breast 2013, 22:1101-1107.
31. Spallarossa P., Garibaldi S., Altieri P., Fabbi P., Manca V., Nasti S., Rossettin P., Ghigliotti G., Ballestrero A., Patrone F., Barsotti A., Brunelli C. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J. Mol. Cell. Cardiol. 2004, 37:837-846.
32. Takamatsu Y., Sunami K., Muta T., Morimoto H., Miyamoto T., Higuchi M., Uozumi K., Hata H., Tamura K. Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study. Int. J. Hematol. 2013, 98:179-185.
33. Tan X., Wang D., Lu X., Wei H., Zhu R., Zhu S.S., Jiang H., Yang Z.J. Doxorubicin induces apoptosis in H9c2 cardiomyocytes: role of overexpressed eukaryotic translation initiation factor 5A. Biol. Pharm. Bull. 2010, 33:1666-1672.
34. Tassan-Mangina S., Codorean D., Metivier M., Costa B., Himberlin C., Jouannaud C., Marie A., Elaerts J., Nazeyrollas P. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur. J. Echocardiogr. 2006, 7:141-146.
35. Valiunas V., Weingart R., Brink P.R. Formation of heterotypic gap junction channels by connexins 40 and 43. Circ. Res. 2000, 86:E42-E49.
36. Van-Dalen E.C., Caron H.V., Dickinson H.O., Kremer L.C.M. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 2011, 15:CD003917. 10.1002/14651858.CD003917.pub4.
37. Wang S., Qu X., Zhao R.C. Clinical applications of mesenchymal stem cells. J. Hematol. Oncol. 2012, 5:1-9.
38. Watkins H., McKenna W.J., Thierfelder L., Suk H.J., Anan R., O'Donoghue A., Spirito P., Matsumori A., Moravec C.S., Seidman J.G., Seidman C.E. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 1995, 332:1058-1065.
39. Yang L., Liu H., Xu X., Wang X., Huang H., Shi W., Jiang S. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Med. Oncol. 2013, 30:720-725.
40. Zhang Y., Kang Y.M., Tian C., Zeng Y., Jia L.X., Ma X., Du J., Li H.H. Overexpression of Nrdp1 in the heart exacerbates doxorubicin-induced cardiac dysfunction in mice. PLoS ONE 2011, 6:e21104.